



**A COURSE ON**

**Pharmaceutical Policy, Pricing, and  
Reimbursement**

**A course for Patient Advocates**

**organised and delivered by**

**The London School of Economics and Political Science,  
LSE Health**

**32 Lincoln's Fields Inn, London WC2A**

**13-14 May 2014**

**DRAFT**

## DAY 1

|                                |  |
|--------------------------------|--|
| 08.45 – 09.00                  | Welcome, introductions, tour de table and course objectives  |
| <b>Session 1</b>               | <b>09.00 – 11.30</b>   |
| Lecture 1:<br>09.00 – 09.45    | Pharmaceuticals in the context of health care – policy, planning, financing and objectives of national pharmaceutical policy<br><i>Professor Kanavos</i>                     |
| Lecture 2:<br>09:45 – 10.30    | Regulatory and intellectual property issues related to prescription pharmaceuticals<br><i>Professor Kanavos</i>  |
| Lecture 3:<br>10.30 – 11.15    | Pharmaceutical Pricing: methods, evidence and why this is relevant for patient advocates: Cost-effectiveness and value-based pricing<br><i>Professor Kanavos</i>             |
| 11.15 – 11.30                  | Coffee/tea break   |
| <b>Session 2</b>               | <b>11.30 – 14.15</b>   |
| Lecture 4:<br>11.30 – 12.30    | Health Technology Assessment (HTA) as a decision-making tool and how it works in practice<br><i>Elena Nicod</i>  |
| Case study 1:<br>12.30 – 13.00 | Case study on the use of HTA in health care decision-making, group work<br><i>Elena Nicod</i>  |
| 13.00 – 13.45                  | Lunch  |
| <b>Session 3</b>               | <b>14.15 – 15.30</b>   |
| Lecture 5:<br>13.45 – 14.30    | The rationale for and use of Risk Sharing and Managed Entry Agreements (MEAs) and their relevance for patients<br><i>Alessandra Ferrario</i>                                 |
| Case study 2:<br>14.30 – 15.15 | Case study Risk Sharing and Managed Entry Agreements<br><i>Alessandra Ferrario</i>   |
| 15.15 - 15.30                  | Coffee/tea break   |
| <b>Session 4</b>               | <b>15.30 – 17.00</b>   |
| Case study 3:<br>15.30 – 16.00 | Debrief on the HTA case study<br><i>Elena Nicod/Professor Kanavos</i>  |
| Lecture 6:<br>16.00 – 16.45    | (1) External price referencing; (2) Principles of pharmaceutical reimbursement: the positive list as the foundation of making coverage decisions<br><i>Professor Kanavos</i> |
| 16.45 – 17.00                  | Wrap up of day 1<br><i>Professor Kanavos</i>   |
| 19.30 – 22.00                  | Les Deux Salons Restaurant   |

## DAY 2

|  |   |
|--|---|
| <b>Session 1</b>                         | <b>09.00 – 10.30</b>  |
| Lecture 1:<br>09.00 – 09.45              | Tools for pharmaceutical reimbursement: Internal price referencing, emphasis on generics, risk sharing and innovative payer schemes<br><i>Professor Kanavos</i> |
| Lecture 2:<br>09.45 – 10.30              | Tools for pharmaceutical reimbursement: public procurement through tendering<br><i>Professor Kanavos</i>  |
| Case study & Lecture 3:<br>10.30 – 11.15 | Prescribing policies: supply-side and demand-side measures, adherence to medicines and quality of care<br><i>Professor Kanavos</i>                              |
| 11.15 – 11.30                            | Coffee/tea break  |
| <b>Session 2</b>                         | <b>11.30 – 13.00</b>  |
| Lecture 4:<br>11.30 – 12.15              | The Demand-side Focus exercise<br><i>Professor Kanavos</i>  |
| Case study: 12.15 – 13.00                | The role of patient advocates: how can patients influence policy making<br><i>Jean Mossman</i>  |
| 13.00 – 13.45                            | Lunch   |
| <b>Session 3</b>                         | <b>13.45 – 15.30</b>  |
| <b>Panel session (TBC)</b>               | Chaired by <i>Ms Mossman and Professor Kanavos</i>  |
| 13.50-14.10                              | Patient evidence: HTA body's perspective<br><i>Heidi Livingstone, NICE</i>  |
| 14.10-14.30                              | Patient evidence: The industry's perspective<br><i>Dr Adam Heathfield, Pfizer</i>   |
| 14.30-14.50                              | Patient evidence: The regulator's perspective<br><i>Dr Isabelle Moulon, European Medicines Agency</i>   |
| 14.50-15.10                              | Patient evidence: The patient's perspective<br><i>Eibhlin Mulroe, CEO, Irish Platform for Patient Organisations, Science and Industry</i>                       |
| 15.10-15.30                              | Discussion and Q & A  |
| 15.30 - 15.45                            | Coffee/tea break  |
| <b>Session 4</b>                         | <b>15.45 – 17.15</b>  |
| Lecture 5:<br>15.45 – 16.15              | Distribution policies and their effectiveness<br><i>Professor Kanavos</i>   |
| Lecture 5 (contd):<br>16.15 – 16.45      | Cost-sharing policies and their impact on influencing patient demand<br><i>Professor Kanavos</i>  |
| 16.45 – 17.00                            | Course evaluation   |
| 17.00 – 17.15                            | Wrap up of day 2 and departures   |